FDA Speeds Up Muscular Dystrophy Baby Tests
Published Date: 6/26/2025
Rule
Summary
The FDA is officially putting the muscular dystrophy newborn screening test into a special safety category called Class II. This means the test will have clear rules to keep it safe and effective, helping babies get diagnosed early. This change makes it easier for new, helpful tests to reach patients faster without extra red tape.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Class II safety rules for newborn test
If you are a parent of a newborn, the FDA has classified the muscular dystrophy newborn screening test as Class II (special controls). This sets specific safety and effectiveness rules for the test to help ensure it is safe and works as intended.
Easier access to new newborn tests
If you are a parent of a newborn, the FDA says this change will enhance patients' access to beneficial innovative devices by reducing regulatory burdens. That means new muscular dystrophy newborn screening tests may reach babies faster and could help with earlier diagnosis.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16714, Agency Information Collection Activities; Proposed Collection; Comment Request; Third Party Disclosure and Recordkeeping Requirements for Reportable Food
The Food and Drug Administration (FDA or the Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection provisions of FDA's third-party disclosure and recordkeeping requirements for reportable food.
2026-16712, Agency Information Collection Activities; Proposed Collection; Comment Request; Imports and Electronic Import Entries
The FDA wants your thoughts on how they collect info about imports and electronic import entries. If you’re involved in importing goods, this could affect you! They’re asking for comments by October 16, 2026, to help improve the process without adding extra costs or hassle.
2026-16715, Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational New Drug Application Requirements
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
Previous / Next Documents
Previous: 2025-11794, Medical Devices; Immunology and Microbiology Devices; Classification of the Herpes Simplex Virus Nucleic Acid-Based Assay for Central Nervous System Infections
The FDA is officially putting the herpes simplex virus test for brain infections into a special safety category called Class II. This means the test will have clear rules to keep it safe and effective, helping patients get better access to this important tool. The change aims to make things smoother for companies without costing extra time or money.
Next: 2025-11802, Special Local Regulation; Marine Events; Annual Bayview Mackinac Race, Lake Huron, MI
The Coast Guard is setting special rules for the Bayview Mackinac Race on Lake Huron to keep everyone safe. Boats can’t enter the race area without permission during the event, so racers and other boaters need to plan ahead. This helps protect both the race and regular boat traffic from accidents.